摘要
目的分析慢性阻塞性肺疾病(慢阻肺)呼吸衰竭患者接受沙美特罗替卡松粉吸入剂(舒利迭)治疗后的肺通气和肺换气功能情况。方法 72例慢阻肺呼吸衰竭患者,随机分为对照组和观察组,各36例。对照组使用常规药物治疗,观察组在对照组基础上使用舒利迭治疗,观察比较两组患者治疗前后肺通气和肺换气功能。结果治疗前两组每分钟最大通气量(MVV)、气道阻力(Raw)、最大呼气中段流量(MMF)比较差异无统计学意义(P>0.05);治疗3、7 d后,观察组MVV、MMF高于对照组,Raw低于对照组,差异具有统计学意义(P<0.05)。治疗前两组最大吸气压(PImax)、最大呼气压(PEmax)、一氧化碳弥散量(DLCO)比较差异无统计学意义(P>0.05);治疗3、7 d后,观察组PImax、PEmax、DLCO均高于对照组,差异具有统计学意义(P<0.05)。结论慢阻肺呼吸衰竭患者接受舒利迭治疗效果突出,患者的肺通气和肺换气功能显著改善,临床中值得推广使用。
Objective To analyze the effect of salmeterol xinafoate and fluticasone propionate powder for inhalation （seretide） on pulmonary ventilation and pulmonary aeration function in chronic obstructive pulmonary disease patients with respiratory failure. Methods A total of 72 chronic obstructive pulmonary disease patients with respiratory failure were randomly divided into control group and observation group, with 36 cases in each group. The control group was treated with conventional drug, and the observation group was treated with seretide on the basis of the control group. Observation and comparison were made on pulmonary ventilation and pulmonary aeration function before and after treatment between two groups. Results Before treatment, both groups had no statistically significant difference in maximal voluntary ventilation （MVV）, airway resistance（Raw）and maximal mid-expiratory flow （MMF） （P〉0.05）. After 3 and 7 d of treatment, the observation group had higher MVV and MMF than the control group , and lower Raw than the control group. Their difference was statistically significant （P〈0.05）. Before treatment, both groups had no statistically significant difference in maximal inspiratory pressure（Pimax）and maximal expiratory pressure （PEmax） and diffusion capacity of carbon monoxide （DLCO） （P〉0.05）. After 3 and 7 d of treatment, the observation group had higher PImax, PEmax and DLCO than the control group, and the difference was statistically significant （P〈0.05）. Conclusion Seretide shows prominent treatment effect for chronic obstructive pulmonary disease patients with respiratory failure, and significantly improve their pulmonary ventilation and pulmonary aeration function. It is worthy of clinical promotion and application.
出处
《中国现代药物应用》
2018年第3期71-72,共2页
Chinese Journal of Modern Drug Application
关键词
沙美特罗替卡松粉吸入剂
慢性阻塞性肺疾病
呼吸衰竭
肺通气
肺换气
Salmeterol xinafoate and fluticasone propionate powder for inhalation
Chronic obstructive pulmonary disease
Respiratory failure
Pulmonary ventilation
Pulmonary aeration
